We have examined the role of erbB-2 expression in the modulation of cellular toxicity to cisplatin. We have demonstrated that treatment of NIH3T3-erbB-2 cells, which overexpress the p185 erbB-2 product of the human erbB-2 gene, with a monoclonal antibody directed against the extracellular domain (TAb-250), results in enhanced cisplatin cytotoxicity. A similar enhancement was obtained when cells were exposed to herbimycin A and its analogue CP127 374, both of which inhibit tyrosine kinase activity. Using the host cell reactivation (HCR) of reporter gene expression from cisplatindamaged plasmid and unscheduled DNA synthesis (UDS) following cisplatin treatment of cells, we have found that modulation of erbB-2 by TAb-250 was associated with inhibition of DNA repair. TAb-250 alone, under conditions which modulate DNA repair, slightly reduces the S-phase of the cell cycle, while cisplatin induced arrest at S and G 2 phases. Combination of TAb-250 and cisplatin only slightly prevented cisplatin-induced S and G 2 blocks. Since the ras pathway is one of the major signaling components coupled to erbB-2, we have examined the role of ras in DNA repair regulation. Transient expression of a ras dominant negative mutant, Asn-17-ras H , prevents DNA repair modulation by TAb-250, suggesting that the erbB-2 receptor regulates DNA repair mechanism(s), at least in part, through ras-coupled pathway(s).
Introduction
Some current clinical strategies in cancer therapy are targeted at the induction of apoptosis in tumor cells. It is believed that apoptosis may be triggered through initial activation of speci®c receptor tyrosine kinases (RTKs) located on the plasma membrane. This hypothesis is supported by numerous studies which show that an early response to cancer treatment with drugs, such as cisplatin (cis-DDP) and adriamycin, is the activation of several cell signaling pathways, including the mitogen-activated protein (MAP) kinase cascade, stress activated protein (SAP) kinase cascade, and protein kinase C (Vich and Triton, 1991; Derijard et al., 1994; Kharbanda et al., 1995; Zhang et al., 1995; Gately et al., 1996; Tyrrell, 1996; Zanke et al., 1996) . It is also known that alterations of growth factor receptors aect cellular response to anticancer drugs and may lead to drug resistance (Nishikawa et al., 1992; Baselga et al., 1993; Benz et al., 1993; Dickstein et al., 1995) . Inversely, modulation of these receptors by speci®c ligands or antibodies potentiate drug ecacy in breast and ovarian cancer cells (Hancock et al., 1991; Baselga et al., 1993; Arteaga et al., 1994; Pietras et al., 1994) .
Among growth factor receptors, the erbB family of receptor tyrosine kinases (RTKs), which include epidermal growth factor receptor (EGFr/erbB-1), erbB-2/p185, erbB-3/p160, and erbB-4/p180, were found to be altered in human cancers (Salmon et al., 1987; Kern et al., 1990; Shi et al., 1992) . In some cases, their overexpression was associated with shorter patient survival (Earp et al., 1995) . Among the RTK members, erbB-2 was found to be overexpressed in many human cancers including lung, breast, ovarian, and oral cancers (Schneider et al., 1989; Weiner et al., 1990; Shi et al., 1992) . The erbB-2 proto-oncogene encodes for a 185 kDa transmembrane glycoprotein (p185) which has a tyrosine kinase activity homologous to the EGF receptor (Dougall et al., 1994) . Previous studies indicate that erbB-2 overexpression can induce cell transformation and tumorigenesis both in vitro and in transgenic mice (Di Fiore et al., 1987; Muller et al., 1988) . Antibodies against p185 were found to reverse the transformant phenotype in vitro and in vivo (Drebin et al., 1985 (Drebin et al., , 1986 Kastsumata et al., 1995) . Furthermore, treatment of cells overexpressing erbB-2 with these antibodies was found to potentiate the cytotoxic eects of anticancer drugs, particularly cis-DDP, both in vitro (Arteaga et al., 1994) and in vivo (Pietras et al., 1994) . The molecular mechanisms involved in the synergism between p185 activation by antibody and cis-DDP cytotoxicity are yet unknown. However, there is some evidence that this eect may be related to the inhibition of DNA repair pathways, as a result of agonistic action of the antibody (Arteaga et al., 1994; Pietras et al., 1994) .
In this study, we report that the modulation of erbB-2 activity by a speci®c antibody, TAb-250, signi®cantly enhances the cytotoxic eect of cis-DDP by mechanisms involving downregulation of DNA repair. This modulatory eect is mediated, at least in part, by the ras signal transduction pathway, since expression of a dominant negative ras mutant prevents the inhibition of DNA repair following treatment with TAb-250.
Results
Eect of TAb-250 on cellular response to cis-DDP NIH3T3-erbB-2 cells have shown stable expression of p185, as compared to the non-transformed parental cell line, NIH3T3 (Figure 1) . Treatment of NIH3T3-erbB-2 with the antibody, TAb-250, at concentrations as low as 1 mg/ml induces the autophosphorylation of the tyrosine residues (Figure 1 ), in agreement with previous studies (Di Fiore et al., 1987; Arteaga et al., 1994) . Figure 2 illustrates the cytotoxic response of NIH3T3-erbB-2 to cis-DDP treatment alone or in combination with TAb-250, as measured by the MTT assay. The concentration of cis-DDP which reduced the growth of the cells by 50% (IC 50 ) was 1.15+0.12 mM in presence of cis-DDP alone and 1.19+0.17 mM in combination with control IgG1 antibody. As compared to cells treated with cis-DDP in the presence of IgG1, pretreatment with 1 mg/ml TAb-250 followed by cis-DDP treatment (TAb-250 was added 5 min prior to cis-DDP treatment) lowered the IC 50 value of cis-DDP by approximately 50% to 0.55 mM (Figure 2 ). Treatment with 10 mg/ml TAb-250 lowered the IC 50 value of cis-DDP by an additional 20% to 0.32 mM. This same synergistic interaction was observed in NIH3T3-neu cells (NIH3T3 cells transfected with the erbB-2 proto-oncogene rat homologue, neu) upon co-treatment with the anti-neu antibody and cis-DDP (Drebin et al., 1985) (results not shown).
Eect of herbimycin A and its analog CP127 374 on cellular response to cis-DDP We have examined the eect of two tyrosine kinase inhibitors, herbimycin A and its analogue CP127 374, on the cellular response to cis-DDP-induced DNA damage. Previous research provides evidence that these agents not only inhibit the tyrosine kinase activity of p185, but also cause its general depletion (Miller et al., 1994a,b) . As shown in Figure 3 , pretreatment of cells (for 1 h) with dierent concentrations (Figure 3a) of herbimycin A or CP127 374 signi®cantly potentiated the cytotoxic eect of cis-DDP (Figure 3b ). The observed synergistic action was more extensive with CP127 374, where concentrations of 10 nM (non-toxic) and 50 nM (20% cell toxicity) lowered the IC 50 value of cis-DDP by approximately 50% and 70%, respectively. The use of toxic concentrations of both herbimycin A and CP127 374 with cis-DDP con®rmed an additive eect.
Eect of TAb-250 on DNA repair capacity A major cellular defence mechanism by which cells respond to the cytotoxic eect of cis-DDP is via activation of DNA repair pathways (Hoeijmakers et al., 1996; Wood et al., 1995; Sancar, 1994) . We have examined the overall repair capacity of cells subjected to conditions which modulate the cytotoxic eects of cis-DDP. Two assays were used: the host cell reactivation (HCR) of reporter gene expression, which re¯ects the capacity of cells to repair plasmids damaged by cis-DDP (Yen et al., 1995; Zeng-Rong et al., 1995) and unscheduled DNA synthesis (UDS) which re¯ects cellular ability to repair damage to genomic DNA (Johnson et al., 1987) . As shown with the host cell reactivation assay in Figure 4 , pretreatment of the pRSV-CAT plasmid with varying concentrations of cis-DDP (0.5 ± 1.5 mM) followed by transient transfection into NIH3T3-erbB-2, reveals a reduction in chloramphenicol acetyl transferase enzyme (CAT) expression, . The addition of a higher concentration of the antibody resulted in an even greater reduction of CAT expression, as evidenced by a 64% reduction in CAT activity following 10 mg/ml TAb-250 treatment of cells transfected with pRSV-CAT-cis-DDP (0.75 mM). As shown in the UDS assay ( Figure 5 ), TAb-250 was also found to inhibit DNA repair by approximately 40% over cis-DDP alone. The results from both of these assays suggest the presence of a synergism between cis-DDP and TAb-250 in relation to DNA repair inhibition. It should be noted that TAb-250 treatment has no eect on transfection eciency (as revealed by both control pRSV-CAT and b-galactosidase plasmid transfections, not shown), and strand breaks were not detected in the plasmids treated with cis-DDP (see plasmid puri®cation steps in Material and methods). Furthermore, TAb-250 has no eect on DNA repair activity in parental NIH3T3 cells (not shown).
Eect of TAb-250 on cell cycle distribution Table 1 shows the eects on NIH3T3-erbB-2 cell cycle distribution following treatment with TAb-250 or cis-DDP alone, as well as the combined treatment. Serumstarved NIH3T3-erbB-2 cells were treated with 5 mg/ml TAb-250 for 24 h. No signi®cant eect on the Eect of TAb-250 on the host cell reactivation capacity. Cells at 60% con¯uence were serum starved for 24 h and then transfected with pRSV-CAT damaged with cis-DDP, in the absence (control, treated with IgG1) or presence of TAb-250, for 5 h. Transfection medium was then replaced with regular medium, in the absence or presence of TAb-250, for an additional 48 h. Cell extracts were prepared for CAT enzyme assay as described in Materials and methods distribution of various cell cycle phases was observed with the antibody alone. Treatment with cis-DDP blocked the cell cycle at S and G2 phases in agreement with previous reports (Eastman, 1990; Lock and Ross, 1990) . Co-treatment of cells with TAb-250 and cis-DDP only slightly prevented a blockade at S/G2 in comparison with cis-DDP alone.
Eect of ras inhibition on DNA repair modulation
The following experiments were conducted to investigate the involvement of the ras signaling pathway in the regulation of DNA repair. In Figures 6a to c, we report our results from the transient expression of two mammalian expression vectors, Asn-17-ras H mutant (Feig and Cooper, 1988) and Val-12-ras H mutant (Tobin et al., 1982) in NIH3T3-erbB-2 cells. Each vector was chosen by its selective interaction with the ras pathway: Asn-17-ras H is known to block the ras pathway, while Val-12-ras H is known to enhance ras activity. A series of experiments were conducted initially to verify the integrity of the experimental protocol and vector activity. Figure 6a shows that expression of Asn-17-ras H and Val-12-ras H had no signi®cant eect on endogenous CAT activity. Similarily, treatment with the TAb-250 antibody alone had negligible eects on pRSV-CAT expression. Cotransfection of these vectors with the SRE-CAT, the CAT reporter gene controlled by the c-fos serum responsive element (Blenis, 1993; Sun et al., 1994) , con®rmed either a strong inhibitory eect on CAT expression (when cotransfected with Asn-17-ras H ) or a stimulatory eect (when cotransfected with Val-12-ras H ). Furthermore, the cotransfection of the Asn-17-ras H vector with cis-DDP untreated pRSV-CAT induced only a slight inhibition of CAT activity while Val-12-ras H had no signi®cant eect (Figure 6b ). Cotransfection of pRSV-CAT previously damaged with 0.75 mM cis-DDP (a concentration that resulted in a 40 ± 50% reduction in CAT activity, as shown in Figure 4b ) with the Asn-17-ras H mutant, signi®cantly reduced the modulatory eect of TAb-250 on DNA repair (Figure 6c ). No such eects were observed in parental NIH3T3 cells or in cells transfected with control empty vector, pDCR. Cotransfection of pRSV-CAT (treated with the same concentration of cis-DDP) and Val-12-ras H (Tobin et al., 1982; Joneson et al., 1996) enhanced host cell reactivation and the addition of TAb-250 induced inhibition of CAT expression (Figure 6c ).
Discussion
Cisplatin (cis-DDP), as well as a variety of anticancer drugs, exert their action in part by inducing the formation of covalent DNA adducts and DNA crosslinking. These lesions compromise cell proliferation and trigger apoptosis. Numerous cellular defence mechanisms have been shown to confer resistance to cis-DDP, among which is the upregulation of DNA repair mechanisms. In particular, nucleotide excision repair has been suggested to play an important role in the removal of bulky adducts (reviewed in Sancar, 1994; Hoeijmakers et al., 1996) . DNA Nucleotide Excision Repair (NER) is a multistep process during which damaged bases are recognized and removed in the form of oligomers. NER involves several steps, including the recognition of DNA damage, incision/ excision of the damaged strand, patch synthesis and ligation of the new strand. An intricate inter-relationship exists between NER, transcription, and several other processes that regulate the cell cycle (reviewed in Hoeijmakers et al., 1996) , providing evidence that the co-ordination of these mechanisms in response to DNA Figure 5 Eect of TAb-250 on DNA repair synthesis. DNA repair synthesis was determined using the unscheduled DNA synthesis assay. Con¯uent cells in which the semi-conservative DNA synthesis was completely inhibited were treated with 20 mM cis-DDP dissolved in medium containing 1% serum and 10 mCi/ ml [ 3 H]-dThd, in the absence or presence of 10 mg TAb-250, for 2 h. Cells were then washed twice with PBS and incubated in a fresh media containing 1% serum and 10 mCi/ml [ 3 H]-dThd for an additional 4 h, in the absence or presence of 10 mg TAb-250. DNA was then extracted as described in Materials and methods Figure 6 Eect of ras modulation on TAb-250 induced DNA repair inhibition. Cells at 60% con¯uence were serum starved for 24 h and then cotransfected with 2 mg untreated pRSV-CAT plasmid or pRSV-CAT damaged with cis-DDP, 2 mg Asn-17-ras H , 2 mg Val-12-ras H , or control vectors, in the absence or presence of 10 mg TAb-250. Control vectors were used to bring the ®nal plasmid concentration in transfection medium to 4 mg. After 5 h, transfection was stopped and cells were incubated in fresh medium, in the absence or presence of 10 mg/ml TAb-250, for an additional 48 h. For each condition, CAT activity was determined in cells treated with 10 mg/ml IgG1 (control), or TAb-250. After 5 h transfection medium was replaced with regular medium, either with or without 10 mg/ml of TAb-250 for an additional 48 h. Cell extracts were prepared for CAT assay as described in Materials and methods. SRE-CAT plasmid was used to con®rm the eciency of Asn- (Yen et al., 1995; Zeng-Rong et al., 1995; reviewed in Chaney and Sancar, 1996) , but the molecular mechanisms of altered DNA repair in drug-resistant cells as well as their relevance to the situation in vivo are still unknown.
Numerous studies have shown that overexpression of growth factor receptors is associated with altered cellular response to DNA damage and DNA repair. We have reported a direct correlation between the overexpression of the erbB-2 proto-oncogene product, p185, drug resistance, and elevated DNA repair capacity in lung cancer cells (Paterson et al., 1996) . In breast and ovarian cancer cells overexpressing erbB-2, antibodies against p185 increased sensitivity to drugs by mechanisms unrelated to drug transport but through DNA repair inhibition (Arteaga et al., 1994; Pietras et al., 1994) .
Our study has shown that the modulation of erbB-2, either by antibody directed against the extracellular domain or compounds that inhibit receptor tyrosine kinase activity, leads to increased cell sensitivity to cis-DDP, in agreement with previous studies (Arteaga et al., 1994; Pietras et al., 1994) . Enhanced drug response by TAb-250 correlated with inhibition of the overall DNA repair capacity, as estimated by two independent assays: the host cell reactivation and unscheduled DNA repair synthesis. While the former measures repair in extragenomic DNA (episomal DNA), the second measures repair in genomic DNA of intact cells. Our data clearly indicate that modulation of erbB-2 inhibits DNA repair in both assays, suggesting that erbB cell signaling regulates DNA repair either directly, or indirectly through other mechanisms such as cell cycle checkpoints. Cell cycle checkpoint regulatory mechanisms involve various cyclins and cyclin-dependent kinases (CDKs) (Hartwell and Kastan, 1994) . The most studied checkpoint mechanism involves cell cycle arrest at G 1 /S, following DNA damage. G 1 /S arrest, which is believed to be required for DNA repair, occurs through the interaction between p53 and the CDK inhibitor, p21 WAF1 , or other cell related genes such as PCNA, RPA and GADD45 (Smith et al., 1994) . Recent studies have shown that treatment with anti-erbB-2 antibodies, or erbB-3/erbB-4 ligands (neuregulins), induced p53 and p21 WAF1 expression (Bacus et al., 1996) , suggesting that modulation of erbB receptors aects cell cycle control mechanisms. In our study, however, cell cycle analysis indicates that the DNA repair modulatory eect cannot be fully explained by dierences in cell cycle, since only a minor eect on cell progression was observed under conditions which modulate cis-DDP toxicity and DNA repair by at least 50%. Furthermore, DNA repair inhibition was also observed in the UDS assay, where cells were arrested at G 0 /G 1 and DNA semi-conservative synthesis was minimal. Herbimycin A, a tyrosine kinase inhibitor which also modulates cis-DDP response, was found to block the G 1 /S transition of mouse ®broblasts (Kuzumaki et al., 1996) , a mechanism which may lead to either more ecient repair or to apoptosis. The former is unlikely, as herbimycin A enhances cis-DDP toxicity. These arguments suggest that nuclear events in response to the modulation of erbB-2 may lead to direct regulation of DNA repair mechanisms. Inhibition of DNA repair can enhance cytotoxicity and induce apoptosis, but the mechanisms which aect cellular decisions to repair and survive or undergo apoptosis need to be characterized. A recent discovery found that overexpression of erbB-2 in estrogen positive MCF7 breast cancer cells led to enhanced expression of the antiapoptotic proteins Bcl2 and Bcl-Xl, and suppression of tamoxifen-induced apoptosis (Kumar et al., 1996) . This ®nding supports the hypothesis that erbB receptor overexpression may create an imbalance between DNA repair and apoptotic pathways.
Common substrates associated with activated receptor tyrosine kinases (RTKs) are also coupled to the erbB-2 receptor, including the ras GTPaseactivating protein (GAP), the c-raf proto-oncogene product serine/threonine kinase (RAF-1) and the 85 kDa component of phosphatidylinositol-3-kinase (Jallal et al., 1992) . Many of these pathways are also induced by cis-DDP (Vich and Triton, 1991; Derijard et al., 1994; Kharbanda et al., 1995; Zhang et al., 1995; Gately et al., 1996; Tyrrell, 1996; Zanke et al., 1996) . We have initially focused on the possible role of the ras signaling pathway on DNA repair modulation because (i) erbB-2 activates ras, MAP kinases and stimulates transcriptional activation of the early responsive genes, fos and jun (Sistonen et al., 1989; Satoh et al., 1990; Dougall et al., 1994) ; (ii) regulation of p21 ras expression through MAP kinase pathways has been demonstrated ; (iii) treatment with the tyrosine phosphatase inhibitor, sodium orthovanadate, enhances phosphotyrosine content of p185 and GAP (Jallal et al., 1992) ; (iv) concomitant overexpression of erbB-2 and a high level of MAP kinase was associated with resistance to low doses of adriamycin (Muss et al., 1994) ; (v) heregulin, the ligand for erbB-3 and erbB-4, activated MAP kinase (ERK) and c-jun Kinase (JNK) in breast cells overexpressing erbB-2 (Karunagaran et al., 1996) . This ligand activation was prolonged in cells overexpressing erbB-2 (Karunagaran et al., 1996) . Furthermore, it has been shown that heregulin activates the ras/raf/MAP kinase pathway via its interaction with erbB receptors (Shearer et al., 1996) .
Our study has clearly indicated that DNA repair modulation by TAb-250 is mediated, at least in part, by the ras pathway. Expression of the Asn-17-ras H mutant (previously shown to decrease the anity of p21 ras for GTP 20-to 40-fold without signi®cantly aecting its anity for GDP) (Feig and Cooper, 1988) signi®cantly prevented DNA repair modulation by TAb-250. However, our CAT activity results showed that Asn-17-ras H expression did not completely prevent repair inhibition by TAb-250. This partial eect may be explained by the possibility that Asn-17-ras H blocks endogenous ras incompletely, or that other erbB-2 components independent from ras may also be involved.
The multiplicity of proteins involved in DNA nucleotide excision repair and the limited information on their regulation makes it dicult, at this stage, to attribute any speci®c role for the connection between erbB-2, ras signaling, and a speci®c DNA repair protein. However, it is likely that some of these repair proteins may be regulated by phosphorylation mechanisms through ras signaling. Serine/threonine-phospha-tase inhibitors were found to inhibit DNA repair, suggesting that serine/threonine protein phosphorylation is involved in the regulation of DNA repair proteins (Ariza et al., 1996; R Wood, personal communication cited in Hoeijmakers et al., 1996) . Hyperphosphorylation of RPA replication protein, following DNA damage, was reported to play a role in cell cycle arrest and DNA repair (Carty et al., 1994) . Taken together, these results suggest that the phosphorylation/dephosphorylation status of some DNA repair proteins plays a role in the regulation of DNA repair mechanisms. 
Materials and methods

Chemicals and reagents
Cell culture
The murine ®broblasts, NIH3T3 and NIH3T3 cells transfected with the human erbB-2 gene (NIH3T3-erbB-2), were maintained in Dulbecco's modi®ed Eagle's medium (DMEM, Mediatech, Washington, DC) supplemented with 10% calf serum and antibiotics. Cells were maintained in an atmosphere of 5% CO 2 .
Cytotoxicity
Exponentially growing cells (1610 3 cells/100 ml) were seeded in 96 well plates and incubated for 16 h. Cells were serum starved overnight then treated continuously with TAb-250 or tyrosine kinase modulators, followed by cisplatin. Cell survival was evaluated 96 h later, by replacing the culture media with 150 ml fresh medium containing 10 mM 4-(2-hydroxyethyl)-1-piperazineethamesulfonic acid buer, pH 7.4. Next, 50 ml of 2.5 mg/ml of 3-(4,5-dimethylthiazo-2-yl)-2,5-diphenyltetrazolium bromide (MTT, Sigma, St Louis, MO) in PBS, pH 7.4, were added. After 4 h of incubation at 378C, the medium and MTT were removed and 200 ml of DMSO were added to dissolve the precipitate of reduced MTT, followed by addition of 25 ml glycine buer (0.1 M glycine plus 0.1 M NaCl, pH 10.5). Plates were then shaken for 15 min and the absorbance was determined at 570 nm with a microplate reader (BIORAD, model 450). The IC 50 was calculated as the dose of drug causing a 50% reduction in the absorbance compared to untreated cells.
Immunoprecipitation and Western blot analysis
Cells were grown in serum supplemented medium until 70% con¯uence in 75 cm 2¯a sks. Cells were then washed twice in serum-free medium and further incubated in serum-free medium for 24 h. Cells were either treated with TAb-250 or IgG1 for 10 min. Medium was removed and cells were washed twice in cold PBS and then lysed directly using lysis buer (1% Triton X-100, 10 mM TrisHCl pH 8.0, 60 mM KCl, 1 mM EDTA, 1 mM DTT, 0.5% NP-40, 0.5 mM phenylmethylsulfonyl¯uoride, 0.01 mg/ml leupeptin, 0.01 mg/ml pepstatin and 0.01 mg/ml aprotonin, 5 mM sodium orthovanadate, 10 mM sodium PPi). The lysate was incubated for 10 ± 15 min at room temperature and then centrifuged at 14 000 g at 48C for 15 min. The supernatant was used to determine protein concentration by Lowry method (Lowry et al., 1951) . One hundred micrograms of protein were immunoprecipitated using a 1 : 250 dilution of the polyclonal anti-erbB-2 antibody (cneu (Ab-1), Oncogene Science, Cambridge, MA). The mixture was then resuspended with 100 ml protein-A agarose and incubated with gentle agitation for 1 h at room temperature. The beads were isolated by centrifugation at 2000 g for 1 min. The immunoprecipitates were then washed three times with lysis buer, resuspended in SDS sample buer, boiled for 5 min, pelleted by centrifugation at 2000 g for 1 min. The eluate was loaded onto an 8% SDS ± polyacrylamide gel, transferred to nitrocellulose (Costar, Cambridge, MA) blocked, then incubated with monoclonal antibody to erbB-2 (c-neu (Ab-3), Oncogene Science) or monoclonal antibody to phosphotyrosine (4G10, Upstate Biotechnology Inc, NY).
Transfection and host cell reactivation assay
The pRSV-CAT plasmid (American Type Culture Collection, Rockville, MD) was used to estimate the capacity of cells to reactivate damaged plasmid. pRSV-CAT was ampli®ed and DNA was prepared by alkaline lysis and cesium chloride/ethidium bromide ultracentrifugation as previously described (Wood et al., 1995; Zeng-Rong et al., 1995) . Plasmid treatment, preparation, and subsequent CAT assays were carried out as described (Yen et al., 1995) . Treated plasmid was further puri®ed using a sucrose density gradient. The pRSV-bgal-plasmid, in which the bgalactosidase gene was driven by RSV promoter, was used as internal control for transfection eciency (Zeng-Rong et al., 1995) . Cells were transfected with 2 mg of each plasmid per well using LipofectAMINE reagent (Gibco/BRL, Burlington, Ontario) as per manufacturer's instructions. After 5 h, cells were incubated in fresh media.
To investigate whether the erbB-2-ras-coupled signaling pathway is required for modulation of DNA repair, we cotransfected cells with cis-DDP-damaged pRSV-CAT in the presence of Asn-17-ras H dominant negative mutant (pDCRHRasN17) (Tobin et al., 1982) , Val-12-ras H (pDCRHRasV12), or control empty vector (pDCR). The SRE-CAT plasmid, in which CAT is driven by the c-fos serum responsive element (Blenis, 1993; Sun et al., 1994) , was used to con®rm the eciency of Asn-17-ras H and Val-12-ras H expression. SRE-CAT is inhibited by Asn-17-ras H and stimulated by Val-12-ras H . Cotransfection experiments were performed using a concentration of 2 mg of each plasmid per well. The control plasmid, pDCR, was used to normalize for the total DNA transfected. After 5 h transfection, transfection media was replaced by regular complete medium.
In all cases, cells were collected 48 h after transfection and cell extracts were used to determine CAT and b-galactosidase activity (Zeng-Rong et al., 1995) . Relative CAT activity was determined as: [%CAT conversion/50 mg protein/5 h]/[bgalactosidase activity/50 mg protein].
Unscheduled DNA synthesis (UDS)
Cells were seeded at 1610 6 cells/well in 6-well plates and kept undisturbed until full con¯uence. Cells were then washed twice with PBS and regular media was substituted for arginine-free medium (MEM Select-Amine R , Gibco/ BRL) containing 2% dialyzed fetal bovine serum. After 24 h, the medium was changed to fresh arginine-free medium containing 1% serum for an additional 48 h. Preliminary experiments (based on kinetic studies of methyl-3 H-thymidine ( 3 H-dThd) incorporation) indicate that under these conditions, DNA semi-conservative synthesis was completely inhibited. Co-treatment with agents that interfere with DNA synthesis, such as Ara-C and hydroxy-urea, was omitted because these agents also inhibit DNA repair. Cells were washed twice with serumfree medium and then treated with cis-DDP [20 mM] in the presence of 10 mCi/ml 3 H-dThd (SA 20 Ci/mmol, Dupont-NEN, Mississauga, Ontario), for 2 h. Cells were then washed twice with PBS and further cultured in fresh arginine-free medium containing 1% serum and 10 mCi/ml 3 H-dThd for an additional 4 h. Cells were washed twice with cold PBS and directly lysed with DNAzol Reagent (Gibco/ BRL). DNA was extracted as per manufacturer's instructions. UDS was estimated as the ratio of [d.p.m./mg DNA in drug-treated] versus [d.p.m./mg DNA incorporation in control] 6100. When indicated, TAb-250 was added at a concentration of 10 mg/ml, 5 min prior to cis-DDP treatment, and maintained during and after drug treatment.
Flow cytometry
Following drug and TAb-250 treatment, cells were washed twice with PBS, and collected after treatment with trypsin.
The cells were then washed with PBS and ®xed in 70% ethanol in PBS. Fixed cells were washed three times with PBS and resuspended, at a density of 2 ± 5610 6 cells/ml, in a solution of PBS containing 522 mg/l Spermine THC (Sigma), 0.5 mM Tris pH 8.0, 35 mg/ml RNase A and 50 mg/ml propidium iodide. FACS analysis was performed on an Epics-Pro®le II¯ow cytometer and cell cycle distribution was determined using the Multicycle program (Pheonix Flow Systems).
